These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 26476131

  • 1. Keratoacanthoma: a distinct entity?
    Gleich T, Chiticariu E, Huber M, Hohl D.
    Exp Dermatol; 2016 Feb; 25(2):85-91. PubMed ID: 26476131
    [Abstract] [Full Text] [Related]

  • 2. Histopathological diagnosis of epithelial crateriform tumors: Keratoacanthoma and other epithelial crateriform tumors.
    Ogita A, Ansai SI, Misago N, Anan T, Fukumoto T, Saeki H.
    J Dermatol; 2016 Nov; 43(11):1321-1331. PubMed ID: 27076258
    [Abstract] [Full Text] [Related]

  • 3. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
    Cabibi D, Aragona F, Guarnotta C, Rodolico V, Zerilli M, Belmonte B, Schillaci L, Aragona F.
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
    [Abstract] [Full Text] [Related]

  • 4. Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin.
    Berger F, Geddert H, Faller G, Werner M, Dimmler A.
    Pathol Res Pract; 2014 Sep; 210(9):596-602. PubMed ID: 24954139
    [Abstract] [Full Text] [Related]

  • 5. Keratoacanthoma: Update on the Debate.
    Nirenberg A, Steinman H, Dixon A.
    Am J Dermatopathol; 2021 Apr 01; 43(4):305-307. PubMed ID: 33395044
    [Abstract] [Full Text] [Related]

  • 6. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas.
    Ho T, Horn T, Finzi E.
    Arch Dermatol; 1991 Aug 01; 127(8):1167-71. PubMed ID: 1863074
    [Abstract] [Full Text] [Related]

  • 7. Subungual keratoacanthoma: a variant of verrucous squamous cell carcinoma of the skin.
    Scarani P, Ghigi G, Bertarelli C, Eusebi V.
    Appl Pathol; 1983 Aug 01; 1(6):339-42. PubMed ID: 6679793
    [Abstract] [Full Text] [Related]

  • 8. Quantitation of S100 protein-positive cells in inflamed and non-inflamed keratoacanthoma and squamous cell carcinoma.
    Korenberg R, Penneys NS, Kowalczyk A, Nadji M.
    J Cutan Pathol; 1988 Apr 01; 15(2):104-8. PubMed ID: 3372786
    [Abstract] [Full Text] [Related]

  • 9. Natural course of keratoacanthoma and related lesions after partial biopsy: clinical analysis of 66 lesions.
    Takai T, Misago N, Murata Y.
    J Dermatol; 2015 Apr 01; 42(4):353-62. PubMed ID: 25676096
    [Abstract] [Full Text] [Related]

  • 10. Keratoacanthoma (KA): An update and review.
    Kwiek B, Schwartz RA.
    J Am Acad Dermatol; 2016 Jun 01; 74(6):1220-33. PubMed ID: 26853179
    [Abstract] [Full Text] [Related]

  • 11. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
    Kanzaki A, Kudo M, Ansai S, Peng WX, Ishino K, Yamamoto T, Wada R, Fujii T, Teduka K, Kawahara K, Kawamoto Y, Kitamura T, Kawana S, Saeki H, Naito Z.
    Int J Oncol; 2016 Mar 01; 48(3):1007-15. PubMed ID: 26782292
    [Abstract] [Full Text] [Related]

  • 12. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma.
    Goldenhersh MA, Olsen TG.
    J Am Acad Dermatol; 1984 Feb 01; 10(2 Pt 2):372-8. PubMed ID: 6368620
    [Abstract] [Full Text] [Related]

  • 13. A puzzling case: SCC or not?
    Simpkin S, Lamont D, Yung A.
    Australas J Dermatol; 2013 Aug 01; 54(3):e74-7. PubMed ID: 22758773
    [Abstract] [Full Text] [Related]

  • 14. Crater/ulcerated form of infundibular squamous cell carcinoma: A possible distinct entity as a malignant (or high-grade) counterpart to keratoacanthoma.
    Misago N, Inoue T, Nagase K, Tsuruta N, Tara-Hashimoto A, Kimura H, Takahara K, Narita T, Narisawa Y.
    J Dermatol; 2015 Jul 01; 42(7):667-73. PubMed ID: 25854192
    [Abstract] [Full Text] [Related]

  • 15. [Multiple self-healing squamous epithelioma, or Ferguson-Smith disease: demonstration of mutations in the TGFβ-receptor].
    Dereure O.
    Ann Dermatol Venereol; 2011 Nov 01; 138(11):790-1. PubMed ID: 22078045
    [No Abstract] [Full Text] [Related]

  • 16. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
    Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C.
    Clin Cancer Res; 2012 Jan 01; 18(1):263-72. PubMed ID: 22096025
    [Abstract] [Full Text] [Related]

  • 17. Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification.
    Misago N, Inoue T, Koba S, Narisawa Y.
    J Dermatol; 2013 Jun 01; 40(6):443-52. PubMed ID: 23414327
    [Abstract] [Full Text] [Related]

  • 18. [A flow cytometric study of the DNA content from paraffin-embedded samples of keratoacanthoma and squamous cell carcinoma].
    Hashimoto Y, Matsuo S, Iizuka H.
    Nihon Hifuka Gakkai Zasshi; 1991 Jun 01; 101(7):701-5. PubMed ID: 1942578
    [Abstract] [Full Text] [Related]

  • 19. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
    Biesterfeld S, Josef J.
    Anticancer Res; 2002 Jun 01; 22(5):3019-23. PubMed ID: 12530035
    [Abstract] [Full Text] [Related]

  • 20. A case of Ferguson-Smith disease.
    Debroy Kidambi A, Cook J, Messenger AG.
    Clin Exp Dermatol; 2017 Jul 01; 42(5):570-572. PubMed ID: 28543632
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.